Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania, Brian Pittman, Patrick D. Skosnik, Shariful A. Syed, Deepak Cyril D’souza
Journal of Psychopharmacology March 20, 2023 DOI: 10.1177/02698811231154852 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Exploratory placebo-controlled, within-subject, fixed-order study Peer reviewed |
|---|---|
| Sample size | 19 |
| Population | Individuals with moderate to severe major depressive disorder |
| Interventions | Psilocybin Placebo |
| Dose | 0.3 mg/kg |
| Duration | 16-week study period |
| Topics | Anxiety Depression Psilocybin |
| Keywords | Placebo Antidepressant Dosing Clinical psychology Hallucinogen Pharmacology |
| Citations | 153 |
| Key points | Depression and anxiety improved after both placebo and psilocybin with no significant difference between conditions, but effect sizes and response/remission rates were higher after psilocybin. |
Abstract
Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature.
Methods: In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with moderate to severe major depressive disorder were administered placebo ( n = 19) followed by psilocybin (0.3 mg/kg) ( n = 15) 4 weeks later. Dosing sessions were embedded within an manualized course of psychotherapy. Enhanced blinding procedures were used. Depression, anxiety, and quality of life were measured over a 16-week study period.
Results: Depression and anxiety significantly improved following both placebo and psilocybin with no significant difference in the degree of change between the two conditions. However, antidepressant effect sizes were larger after psilocybin ( d′ = 1.02–2.27) than after placebo ( d′ = 0.65–0.99) and there were high rates of response (66.7%) and remission (46.7%) following psilocybin administration. Antidepressant effects following psilocybin persisted, on average, for 2 months and there were persisting improvements in mood-related quality of life domains. The strength of mystical-type experience during psilocybin dosing was not correlated with subsequent antidepressant effects.
Conclusions: The results of this exploratory study highlight the complex interplay between expectancy, therapy effects, and drug/placebo effects in psychedelic-assisted psychotherapy studies. Nonetheless, the acute and persisting clinical improvements observed following psilocybin support further study of its potential in the treatment of major depression. Future studies should more explicitly mitigate and measure expectancy effects and assess the impact of repeated dosing and different forms of psychotherapeutic support.
Comparable studies
Other randomized controlled trials on psilocybin for anxiety, most cited first.
Citations in the library
Cited by 144
- Adverse Events in Studies of Classic Psychedelics JAMA Psychiatry September 4, 2024
- Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research May 1, 2024
- History repeating: guidelines to address common problems in psychedelic science Therapeutic Advances in Psychopharmacology 2023
- Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Research November 1, 2023
- Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use Journal of Psychopharmacology June 8, 2023
and 139 more in the library
Cites 29
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 24 more in the library